PL3120863T3 - Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu - Google Patents

Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu

Info

Publication number
PL3120863T3
PL3120863T3 PL16182139.2T PL16182139T PL3120863T3 PL 3120863 T3 PL3120863 T3 PL 3120863T3 PL 16182139 T PL16182139 T PL 16182139T PL 3120863 T3 PL3120863 T3 PL 3120863T3
Authority
PL
Poland
Prior art keywords
compositions
growth factor
plasma levels
achieving desired
glial growth
Prior art date
Application number
PL16182139.2T
Other languages
English (en)
Inventor
Haesun Kim
Anthony O. Caggiano
Original Assignee
Acorda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics, Inc. filed Critical Acorda Therapeutics, Inc.
Publication of PL3120863T3 publication Critical patent/PL3120863T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL16182139.2T 2008-02-29 2009-03-02 Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu PL3120863T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6758908P 2008-02-29 2008-02-29

Publications (1)

Publication Number Publication Date
PL3120863T3 true PL3120863T3 (pl) 2021-02-22

Family

ID=41016663

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09715322T PL2262527T4 (pl) 2008-02-29 2009-03-02 Kompozycje do osiągania w surowicy pożądanych poziomów glejowego czynnika wzrostu 2
PL16182139.2T PL3120863T3 (pl) 2008-02-29 2009-03-02 Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09715322T PL2262527T4 (pl) 2008-02-29 2009-03-02 Kompozycje do osiągania w surowicy pożądanych poziomów glejowego czynnika wzrostu 2

Country Status (11)

Country Link
US (5) US8410050B2 (pl)
EP (3) EP3750551A1 (pl)
JP (2) JP5697455B2 (pl)
CN (2) CN104645315A (pl)
AU (1) AU2009217606B2 (pl)
BR (1) BRPI0908271A2 (pl)
CA (1) CA2717193C (pl)
ES (2) ES2811127T3 (pl)
PL (2) PL2262527T4 (pl)
RU (3) RU2530650C2 (pl)
WO (1) WO2009108390A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2530650C2 (ru) 2008-02-29 2014-10-10 Акорда Терапьютикс, Инк. Способ обеспечения требуемых уровней фактора 2 роста глии в плазме
AU2009292216B2 (en) 2008-07-17 2015-03-05 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
WO2010019275A2 (en) 2008-08-15 2010-02-18 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
KR101933543B1 (ko) 2009-10-14 2018-12-28 아코르다 쎄라퓨틱스 인코포레이티드 말초 신경 손상을 치료하기 위한 뉴레귤린의 용도
AU2011257192A1 (en) * 2010-05-28 2013-01-10 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
CA2845198A1 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
CN104321072A (zh) * 2012-03-30 2015-01-28 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
JP7064197B2 (ja) * 2016-09-23 2022-05-10 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
CN108653274B (zh) * 2017-04-01 2022-09-16 鲁南制药集团股份有限公司 牛蒡子苷元在制备治疗骨髓损伤药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
EP1229925A2 (en) * 1999-11-19 2002-08-14 Axxima Pharmaceuticals Aktiengesellschaft Inhibitors of helicobacter pylori induced gastrointestinal diseases
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1646353A4 (en) * 2003-05-16 2008-06-04 Acorda Therapeutics Inc FUSION PROTEINS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM
WO2005079458A2 (en) * 2004-02-19 2005-09-01 The Regents Of The University Of California ENHANCEMENT OF Th2-DEPENDENT AND INFLAMMATORY RESPONSE
JP2008528697A (ja) 2005-02-02 2008-07-31 ネクサスファーマ・インコーポレイテッド 癌の病因に関連するウィルス感染症を治療するためのアミン誘導体含有組成物および方法
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20080003013A1 (en) * 2006-06-30 2008-01-03 Static Control Components, Inc. Cartridge split rail clip
RU2530650C2 (ru) 2008-02-29 2014-10-10 Акорда Терапьютикс, Инк. Способ обеспечения требуемых уровней фактора 2 роста глии в плазме
EP2553074B1 (en) 2010-04-01 2014-02-26 The Procter and Gamble Company Fabric softener
CA2845198A1 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use

Also Published As

Publication number Publication date
EP2262527B1 (en) 2016-08-03
WO2009108390A2 (en) 2009-09-03
EP3120863B1 (en) 2020-05-06
PL2262527T3 (pl) 2017-07-31
RU2687097C2 (ru) 2019-05-07
RU2019110452A (ru) 2020-10-09
CN102026651B (zh) 2015-06-03
JP5697455B2 (ja) 2015-04-08
CN104645315A (zh) 2015-05-27
JP5964920B2 (ja) 2016-08-03
EP2262527A2 (en) 2010-12-22
US8410050B2 (en) 2013-04-02
AU2009217606A1 (en) 2009-09-03
CA2717193A1 (en) 2009-09-03
US20160367634A1 (en) 2016-12-22
WO2009108390A3 (en) 2010-11-18
AU2009217606B2 (en) 2015-03-05
US20100029559A1 (en) 2010-02-04
ES2811127T3 (es) 2021-03-10
US10675331B2 (en) 2020-06-09
BRPI0908271A2 (pt) 2017-06-13
ES2613177T3 (es) 2017-05-23
US20130345131A1 (en) 2013-12-26
EP3750551A1 (en) 2020-12-16
JP2015042656A (ja) 2015-03-05
EP3120863A1 (en) 2017-01-25
US9744215B2 (en) 2017-08-29
RU2010139906A (ru) 2012-04-10
PL2262527T4 (pl) 2017-07-31
US9272015B2 (en) 2016-03-01
CN102026651A (zh) 2011-04-20
US20180055909A1 (en) 2018-03-01
RU2530650C2 (ru) 2014-10-10
JP2011513310A (ja) 2011-04-28
CA2717193C (en) 2022-08-16
RU2014131265A (ru) 2016-02-20
US20210060128A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
IL228826A0 (en) Low voc latex coating preparations
ZA201103926B (en) Stable sulfoximine-insecticide compositions
PL3120863T3 (pl) Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu
SI2634232T1 (sl) Sestavki
GB0810404D0 (en) Compositions
IL213706A0 (en) Stable insecticide compositions and methods for producing same
IL208324A0 (en) Compositions comprising arnox-inhibitors for the inhibition of reactive oxygen species
GB0812041D0 (en) Compositions
GB0808537D0 (en) Compositions
GB0818804D0 (en) Compositions
SI2470166T1 (sl) Novi sestavki 1-(2-(2,4-dimetil-fenislulfanil)-fenil)piperazina
EP2294199A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING PLANTS
GB0714298D0 (en) Coating compositions
EP2288745A4 (en) COATING COMPOSITIONS
PL2294198T3 (pl) Sposoby i kompozycje do ulepszania roślin
GB0816577D0 (en) Growth factor
HK1152230A (en) Compositions for achieving desired glial growth factor 2 plasma levels
GB0618082D0 (en) Growth factor
HK1166702A (en) Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
HK1148224A (en) Compositions comprising anrnox-inhibitors for the inhibition of reactive oxygen species
GB0922089D0 (en) Compounds, compositions and methods for controlling biofilms
GB0922087D0 (en) Compounds, compositions and methods for controlling biofilms
GB0922424D0 (en) Compounds, compositions and methods for controlling biofilms
HK1166283A (en) Methods and compositions for treating leukemia
GB0922205D0 (en) Controlling biofilms:compounds, compositions and methods